Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees.
Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.
To gain a complete market understanding, Porters Five Force’s analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market.
Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.
The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.